AVIEW LCS vs AVIEW

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW LCS

by Coreline Soft Co.

AVIEW

by Coreline Soft Co.

AI Verdict

Both AVIEW LCS and AVIEW are highly comparable AI-powered solutions from Coreline Soft, providing extensive analysis of lung nodules, emphysema, and coronary artery calcification from CT scans. AVIEW LCS is specifically positioned for lung cancer screening with a focus on low-dose CT scans. AVIEW offers a broader platform that includes additional features like interstitial lung disease pattern analysis and more extensive anatomical segmentation.

Choose AVIEW LCS if…

Choose AVIEW LCS if your primary need is an efficient, integrated, and fully automated AI solution specifically designed for high-volume lung cancer screening programs. This tool excels at providing rapid detection and analysis of lung nodules, alongside concurrent assessment for COPD and coronary artery calcification from a single low-dose CT scan, streamlining initial screening workflows and generating comprehensive reports.

View AVIEW LCS →

Choose AVIEW if…

Choose AVIEW if your clinical practice requires a more comprehensive AI platform for detailed diagnosis and long-term monitoring of a broader range of lung conditions, including advanced characterization of lung nodules and specific interstitial lung disease (ILD) pattern analysis. This solution offers extensive anatomical segmentation, 3D visualizations, and robust follow-up capabilities, making it ideal for in-depth diagnostic evaluations beyond initial screening.

View AVIEW →

For physicians evaluating AI tools for cardiopulmonary assessment, Coreline Soft offers two distinct platforms: AVIEW LCS and AVIEW. While both provide AI-driven analysis of lung cancer, COPD, and coronary artery calcification from CT scans, their primary differentiation lies in their specialized focus and feature sets. AVIEW LCS is specifically designed for lung cancer screening, offering robust automated lung nodule detection, Lung-RADS classification, and detailed nodule volume quantification. It excels in streamlining screening workflows with automated comparisons for follow-up scans and comprehensive report generation, making it ideal for practices heavily involved in lung cancer screening programs.

AVIEW, on the other hand, presents a broader diagnostic platform. While it includes lung nodule detection and CAC scoring, it expands its capabilities with features like automated segmentation of lung lobes and airways, and Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture). This makes AVIEW a more comprehensive solution for general radiology or pulmonology practices requiring a wider range of diagnostic insights beyond just screening. The key practical difference is AVIEW LCS’s dedicated optimization for screening efficiency versus AVIEW’s more expansive diagnostic and analytical toolkit.

Therefore, a physician primarily focused on establishing or enhancing a lung cancer screening program, prioritizing workflow efficiency and standardized reporting for nodules, would likely find AVIEW LCS to be the more tailored choice. Conversely, a physician seeking a versatile AI platform for a broader spectrum of pulmonary and cardiac assessments, including detailed anatomical segmentation and ILD analysis, would benefit more from the comprehensive features offered by AVIEW.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW LCS	AVIEW
Pricing	Contact for pricing	Subscription; one-off payment
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both AVIEW LCS and AVIEW emphasize streamlining radiology workflows, automated reporting, and integration with existing hospital systems (PACS/RIS/CIS). Without specific user interface details or comparative user feedback, it is challenging to definitively differentiate their usability.

Clinical Value

AVIEW

While both tools offer robust features for lung nodule detection, COPD, and coronary artery calcification (CAC) scoring, Tool B explicitly includes 'risk stratification' for CAC and 'Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture)'. These additional capabilities suggest a broader clinical utility and diagnostic scope.

Pricing & Value

AVIEW

Tool B provides more transparency regarding its pricing structure, explicitly stating options for subscription or one-off payments based on the number of installations or users. In contrast, Tool A only indicates 'contact for pricing,' offering no insight into its cost model.

Enterprise Readiness

AVIEW LCS

Both tools demonstrate strong enterprise readiness with flexible deployment options (cloud, hybrid, local) and integration capabilities. However, Tool A explicitly states it 'has_baa': '1', which is a critical component for data privacy and security compliance in healthcare enterprises, providing an added layer of assurance for handling protected health information.

Innovation

AVIEW

While both tools utilize AI for advanced diagnostics, Tool B demonstrates slightly more innovative capabilities with its explicit mention of automated segmentation of complex anatomical structures like airways and coronary arteries. Furthermore, its 'Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture)' represents a sophisticated application of AI for a challenging diagnostic area.

Support & Docs

Tie

Both AVIEW LCS and AVIEW are products from the same company, Coreline Soft. Without specific comparative information on their respective support channels, service level agreements, or documentation quality, it is reasonable to assume they share similar support infrastructure and resources from the parent company.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW LCS	AVIEW
Product Name	AVIEW LCS	AVIEW
Tagline	AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment	AI-Driven Diagnostic Solutions for Medical Imaging
Specialties	Cardiology, Oncology, Pulmonology, Radiology	Cardiology, Pulmonology, Radiology
Automated Lung Nodule Detection/Analysis	Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation	AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score)
Coronary Artery Calcification (CAC) Scoring	Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass)	Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification)
Follow-up Nodule Comparison	Automated comparison of nodules in follow-up CT scans	Follow-up registration and nodule matching for serial CT scans